Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.6 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.17% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (down 1.27% YoY) and the FY2025 annual result came in at $1.7 billion, up 3.8% from the prior year.
• Liabilities and Shareholders Equity declined to $1.6 billion in Q1 2026, from $1.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.9 billion in Q2 2023 to a low of $1.0 billion in Q1 2022.
• A 5-year average of $1.6 billion and a median of $1.7 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 99.83% — and 2024, when it surged 46.78%.
• Tracing LEGN's Liabilities and Shareholders Equity over 5 years: stood at $1.3 billion in 2022, then surged by 38.89% to $1.8 billion in 2023, then retreated by 9.65% to $1.7 billion in 2024, then grew by 3.8% to $1.7 billion in 2025, then dropped by 7.9% to $1.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.6 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.